Cenicriviroc
- Generic Name
- Cenicriviroc
- Drug Type
- Small Molecule
- Chemical Formula
- C41H52N4O4S
- CAS Number
- 497223-25-3
- Unique Ingredient Identifier
- 15C116UA4Y
- Background
Cenicriviroc has been used in trials studying the treatment of HIV-infection/AIDS, AIDS Dementia Complex, Nonalcoholic Steatohepatitis, Human Immunodeficiency Virus, and HIV-1-Associated Cognitive Motor Complex.
Immune Modulators for Treating COVID-19
- Conditions
- Covid19
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Daniel Benjamin
- Target Recruit Count
- 1971
- Registration Number
- NCT04593940
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 45
- Registration Number
- NCT04500418
- Locations
- 🇩🇪
Medical Department of Hepatology and Gastroenterology, Charité University Medicine, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
- Conditions
- COVID-19
- Interventions
- Biological: dornase alfaBiological: IC14Biological: narsoplimab
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 1500
- Registration Number
- NCT04488081
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 193
- Registration Number
- NCT03517540
- Locations
- 🇬🇧
Novartis Investigative Site, Torquay, United Kingdom
Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Allergan
- Target Recruit Count
- 16
- Registration Number
- NCT03376841
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
- Conditions
- Nonalcoholic SteatohepatitisNon-alcoholic Fatty Liver DiseaseLiver Cirrhosis
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 167
- Registration Number
- NCT03059446
- Locations
- 🇩🇪
Universitaetsklinikum Heidelberg - Innere Medizin IV, Heidelberg, Germany
🇩🇪Uniklinik Koeln, Poliklinik fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP), Koeln, Germany
🇬🇧Queen Alexandra Hospital, Portsmouth, United Kingdom
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 1778
- Registration Number
- NCT03028740
- Locations
- 🇺🇸
Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States
🇺🇸Qway Research, LLC, Hialeah, Florida, United States
🇺🇸Options Health Research, Tulsa, Oklahoma, United States
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02684799
- Locations
- 🇺🇸
SeaView Research, Inc., Miami, Florida, United States
PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02653625
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇨🇦University of Calgary, Liver Unit, Calgary, Alberta, Canada
🇨🇦Toronto University Health Center, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.